Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10283728" target="_blank" >RIV/00179906:_____/14:10283728 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/14:10283728
Result on the web
<a href="http://www.dovepress.com/targeted-treatment-for-chronic-lymphocytic-leukemia-clinical-potential-peer-reviewed-article-PGPM" target="_blank" >http://www.dovepress.com/targeted-treatment-for-chronic-lymphocytic-leukemia-clinical-potential-peer-reviewed-article-PGPM</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/PGPM.S55501" target="_blank" >10.2147/PGPM.S55501</a>
Alternative languages
Result language
angličtina
Original language name
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Original language description
Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival(OS) in untreated fit patients; humanized anti-CD52 antibody alemtuzumab and fully human anti-CD20 antibody ofatumumab lead to improvement in refractory disease. Novel small molecule inhibitors such as ibrutinib and idelalisib demonstrated excellent activity and were very recently licensed in relapsed/refractory CLL. Obinutuzumab (GA101) is the newest monoclonal antibody approved for the treatment of CLL. This novel, glycoengineered, type II humanized anti-CD20 antibody is characterized by enhanced antibody-dependent cellular cytotoxicity and direct induction of cell death compared to type I antibodies. Combination of obinutuzumab and chlorambucil yielded significantly better OS in comparison to chlorambucil monotherapy in untreated co
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT13412" target="_blank" >NT13412: Complex assessment of microenvironment and its impact on clinical course of chronic lymphocytic leukemia.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pharmacogenomics and Personalized Medicine
ISSN
1178-7066
e-ISSN
—
Volume of the periodical
8
Issue of the periodical within the volume
2014
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
1-7
UT code for WoS article
—
EID of the result in the Scopus database
—